erlotinib hydrochloride has been researched along with vatalanib in 3 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 276 | 42 | 98 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | vatalanib (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 10 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.4577 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.2013 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.73 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.1192 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.1475 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.378 | |
| Vascular endothelial growth factor receptor 2 | Danio rerio (zebrafish) | 0.49 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Filov, VA; Gershanovich, ML; Imianitov, EN; Stukov, AN | 1 |
| Greten, TF; Manns, MP; Plentz, RR | 1 |
| Adamczak, J; Chatterjee, S; Florin, A; Franz, T; Heukamp, LC; Hinze, Y; Neumaier, B; Schöttle, J; Siobal, M; Ullrich, RT; Wieczorek, C | 1 |
2 review(s) available for erlotinib hydrochloride and vatalanib
| Article | Year |
|---|---|
[Problems in the current target therapy of malignancies].
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Azathioprine; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Phthalazines; Piperazines; Pyridines; Pyrimidines; Quinazolines; Quinolones; Rituximab; Sesquiterpenes; Sesquiterpenes, Guaiane; Trastuzumab | 2005 |
Molecular therapy of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
1 other study(ies) available for erlotinib hydrochloride and vatalanib
| Article | Year |
|---|---|
Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mass Spectrometry; Mice; Mice, Nude; Multimodal Imaging; Phthalazines; Piperidines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2014 |